Global Radiopharmaceutical Market - 2025 -2033
Radiopharmaceuticals Market Size
The global radiopharmaceuticals market size reached US$ 7.91 billion in 2024 from US$ 7.20 billion in 2023 and is expected to reach US$ 19.69 billion by 2033, growing at a CAGR of 10.8% during the forecast period 2025-2033.
Market Overview
The global radiopharmaceuticals market is experiencing rapid expansion, driven by a surge in demand for precision diagnostics and targeted radioligand therapies. Key industry players such as Novartis, Bayer, and Eli Lilly are capitalizing on this growth through strategic acquisitions, R&D investments, and integrated product development. Geographically, North America leads the market in terms of revenue and innovation, while Asia-Pacific is registering the fastest growth, fueled by expanding healthcare access and regulatory support. Looking ahead, the continued convergence of diagnostic and therapeutic agents, alongside improvements in isotope generation, regulatory pathways, and combination regimens, is poised to further propel the market.
Market Dynamics
Drivers:
Rising adoption in various types of cancers is significantly driving the radiopharmaceuticals market growth
The rising adoption of radiopharmaceuticals in multiple cancer types is a significant driver of market growth, as these agents uniquely combine high diagnostic accuracy with targeted therapeutic potential. In prostate cancer, PSMA-targeted PET tracers such as ^68Ga-PSMA-11 and ^18F-DCFPyL have become pivotal in staging and recurrence detection, while the paired therapy ^177Lu-PSMA-617 (Pluvicto) has demonstrated significant survival benefits in metastatic castration-resistant cases.
Neuroendocrine tumors (NETs) similarly benefit from the theranostic pairing of ^68Ga-DOTATATE for imaging and ^177Lu-DOTATATE (Lutathera) for peptide receptor radionuclide therapy (PRRT), offering both precise localization and effective tumor control. In thyroid cancer, ^131I remains a gold-standard therapy, especially in differentiated subtypes, providing a decades-long proof of clinical and commercial viability. Liver cancers have seen growing use of ^90Y microspheres for selective internal radiation therapy (SIRT), which delivers high-dose beta radiation directly to hepatic tumors while sparing healthy tissue.
Additionally, radiopharmaceutical use is expanding into breast cancer, where agents such as ^89Zr-trastuzumab are in trials for HER2-positive tumor imaging, and into glioblastoma, with iodine- and lutetium-labeled agents targeting LAT1 transporters. The broadening spectrum of cancer applications is not only increasing patient volumes eligible for radiopharmaceutical-based management but also encouraging oncologists to integrate these agents earlier in treatment algorithms.
Combined with precision medicine trends, this multi-cancer adoption is catalyzing sustained demand, prompting pharmaceutical majors and isotope suppliers to expand capacity, diversify pipelines, and accelerate R&D collaborations ultimately propelling the global radiopharmaceuticals market toward robust growth in the coming years.
Restraints:
Nuclear waste handling constraints is hampering the growth of the radiopharmaceuticals market
Nuclear waste handling constraints are a significant barrier to radiopharmaceutical market growth because every stage of production, transport, and clinical use generates radioactive byproducts that require specialized disposal. For instance, spent generator columns from ^99Mo/^99mTc systems, unused doses of short-lived isotopes, and contaminated consumables (syringes, vials, shielding) must be treated as radioactive waste. This necessitates licensed storage facilities, trained radiation safety personnel, and compliance with stringent national regulations, which can be costly and time-consuming.
Smaller hospitals and imaging centers, especially in emerging markets, often lack the infrastructure for proper waste containment and decay storage, forcing them to rely on centralized facilities, slowing turnaround times and limiting access to time-sensitive tracers like ^18F and ^68Ga. These challenges can discourage new entrants, restrict the number of approved radiopharmacy sites, and increase overhead costs for existing providers. Ultimately, inefficient or costly nuclear waste handling systems reduce scalability, limit geographical reach, and dampen investment in new radiopharmaceutical production facilities, thereby constraining overall market expansion.
Segmentation Analysis
The global radiopharmaceuticals market is segmented based on type, radioisotope, indication, end-user, and region.
The prostate cancer segment from the indication is dominating the radiopharmaceuticals market with a 21.03% share in 2024
The prostate cancer segment is the dominant indication in the radiopharmaceuticals market due to the rapid global adoption of PSMA-targeted theranostic approaches. Imaging agents like ^68Ga-PSMA-11 and ^18F-DCFPyL have revolutionized disease staging and recurrence detection by offering superior sensitivity compared to conventional imaging, enabling earlier and more precise treatment planning. On the therapeutic side, ^177Lu-PSMA-617 (Pluvicto) has gained regulatory approvals in multiple regions after demonstrating significant improvements in overall survival and quality of life for patients with metastatic castration-resistant prostate cancer in the VISION trial. This success has prompted its integration into standard oncology workflows, leading to high prescription volumes in the U.S., Europe, and Australia.
Moreover, prostate cancer’s high global prevalence over 1.6 million cases expected to occur in 2025 according to the World Health Organization, which creates a large and recurring patient pool, especially in aging male populations. The strong clinical evidence, large addressable market, and increasing reimbursement coverage have solidified prostate cancer’s position as the largest revenue-generating segment in the radiopharmaceuticals industry, outpacing other cancer indications such as neuroendocrine tumors and thyroid cancer.
Geographical Share Analysis
North America is expected to dominate the global radiopharmaceuticals market with a 42.39% in 2024
North America is the dominant region in the radiopharmaceuticals market due to its advanced healthcare infrastructure, strong research ecosystem, and early adoption of cutting-edge nuclear medicine technologies. The U.S. hosts a dense network of cyclotrons, PET/SPECT facilities, and radiopharmacies, enabling efficient production and distribution of short-lived isotopes like ^18F, ^68Ga, and ^99mTc.
Regulatory support from the FDA, including accelerated approval pathways for theranostic agents such as ^177Lu-PSMA-617 (Pluvicto) and ^177Lu-DOTATATE (Lutathera), has fast-tracked commercialization. Leading companies like Novartis, Bayer and Eli Lilly have significant operational bases in the region, ensuring robust supply chains. High per-capita healthcare spending and broad insurance reimbursement encourage adoption of costly but effective radiopharmaceutical therapies, particularly in oncology.
Additionally, a large and growing patient pool for prostate cancer, neuroendocrine tumors, and cardiovascular conditions sustains demand. The presence of top-tier academic and research institutions such as the Mayo Clinic supports continuous clinical trial activity, further driving innovation. Combined with a mature regulatory framework, strong investment climate, and widespread clinical expertise, these factors solidify North America’s leadership in global radiopharmaceuticals market share.
Competitive Landscape
Top companies in the radiopharmaceuticals market include Novartis Pharmaceuticals Corporation, Bayer Corporation, Jubilant DraxImage Inc., Eckert & Ziegler, Telix Pharmaceuticals Limited, and Eli Lilly and Company, among others.
The global radiopharmaceuticals market report delivers a detailed analysis with 58 key tables, more than 70 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
The global radiopharmaceuticals market size reached US$ 7.91 billion in 2024 from US$ 7.20 billion in 2023 and is expected to reach US$ 19.69 billion by 2033, growing at a CAGR of 10.8% during the forecast period 2025-2033.
Market Overview
The global radiopharmaceuticals market is experiencing rapid expansion, driven by a surge in demand for precision diagnostics and targeted radioligand therapies. Key industry players such as Novartis, Bayer, and Eli Lilly are capitalizing on this growth through strategic acquisitions, R&D investments, and integrated product development. Geographically, North America leads the market in terms of revenue and innovation, while Asia-Pacific is registering the fastest growth, fueled by expanding healthcare access and regulatory support. Looking ahead, the continued convergence of diagnostic and therapeutic agents, alongside improvements in isotope generation, regulatory pathways, and combination regimens, is poised to further propel the market.
Market Dynamics
Drivers:
Rising adoption in various types of cancers is significantly driving the radiopharmaceuticals market growth
The rising adoption of radiopharmaceuticals in multiple cancer types is a significant driver of market growth, as these agents uniquely combine high diagnostic accuracy with targeted therapeutic potential. In prostate cancer, PSMA-targeted PET tracers such as ^68Ga-PSMA-11 and ^18F-DCFPyL have become pivotal in staging and recurrence detection, while the paired therapy ^177Lu-PSMA-617 (Pluvicto) has demonstrated significant survival benefits in metastatic castration-resistant cases.
Neuroendocrine tumors (NETs) similarly benefit from the theranostic pairing of ^68Ga-DOTATATE for imaging and ^177Lu-DOTATATE (Lutathera) for peptide receptor radionuclide therapy (PRRT), offering both precise localization and effective tumor control. In thyroid cancer, ^131I remains a gold-standard therapy, especially in differentiated subtypes, providing a decades-long proof of clinical and commercial viability. Liver cancers have seen growing use of ^90Y microspheres for selective internal radiation therapy (SIRT), which delivers high-dose beta radiation directly to hepatic tumors while sparing healthy tissue.
Additionally, radiopharmaceutical use is expanding into breast cancer, where agents such as ^89Zr-trastuzumab are in trials for HER2-positive tumor imaging, and into glioblastoma, with iodine- and lutetium-labeled agents targeting LAT1 transporters. The broadening spectrum of cancer applications is not only increasing patient volumes eligible for radiopharmaceutical-based management but also encouraging oncologists to integrate these agents earlier in treatment algorithms.
Combined with precision medicine trends, this multi-cancer adoption is catalyzing sustained demand, prompting pharmaceutical majors and isotope suppliers to expand capacity, diversify pipelines, and accelerate R&D collaborations ultimately propelling the global radiopharmaceuticals market toward robust growth in the coming years.
Restraints:
Nuclear waste handling constraints is hampering the growth of the radiopharmaceuticals market
Nuclear waste handling constraints are a significant barrier to radiopharmaceutical market growth because every stage of production, transport, and clinical use generates radioactive byproducts that require specialized disposal. For instance, spent generator columns from ^99Mo/^99mTc systems, unused doses of short-lived isotopes, and contaminated consumables (syringes, vials, shielding) must be treated as radioactive waste. This necessitates licensed storage facilities, trained radiation safety personnel, and compliance with stringent national regulations, which can be costly and time-consuming.
Smaller hospitals and imaging centers, especially in emerging markets, often lack the infrastructure for proper waste containment and decay storage, forcing them to rely on centralized facilities, slowing turnaround times and limiting access to time-sensitive tracers like ^18F and ^68Ga. These challenges can discourage new entrants, restrict the number of approved radiopharmacy sites, and increase overhead costs for existing providers. Ultimately, inefficient or costly nuclear waste handling systems reduce scalability, limit geographical reach, and dampen investment in new radiopharmaceutical production facilities, thereby constraining overall market expansion.
Segmentation Analysis
The global radiopharmaceuticals market is segmented based on type, radioisotope, indication, end-user, and region.
The prostate cancer segment from the indication is dominating the radiopharmaceuticals market with a 21.03% share in 2024
The prostate cancer segment is the dominant indication in the radiopharmaceuticals market due to the rapid global adoption of PSMA-targeted theranostic approaches. Imaging agents like ^68Ga-PSMA-11 and ^18F-DCFPyL have revolutionized disease staging and recurrence detection by offering superior sensitivity compared to conventional imaging, enabling earlier and more precise treatment planning. On the therapeutic side, ^177Lu-PSMA-617 (Pluvicto) has gained regulatory approvals in multiple regions after demonstrating significant improvements in overall survival and quality of life for patients with metastatic castration-resistant prostate cancer in the VISION trial. This success has prompted its integration into standard oncology workflows, leading to high prescription volumes in the U.S., Europe, and Australia.
Moreover, prostate cancer’s high global prevalence over 1.6 million cases expected to occur in 2025 according to the World Health Organization, which creates a large and recurring patient pool, especially in aging male populations. The strong clinical evidence, large addressable market, and increasing reimbursement coverage have solidified prostate cancer’s position as the largest revenue-generating segment in the radiopharmaceuticals industry, outpacing other cancer indications such as neuroendocrine tumors and thyroid cancer.
Geographical Share Analysis
North America is expected to dominate the global radiopharmaceuticals market with a 42.39% in 2024
North America is the dominant region in the radiopharmaceuticals market due to its advanced healthcare infrastructure, strong research ecosystem, and early adoption of cutting-edge nuclear medicine technologies. The U.S. hosts a dense network of cyclotrons, PET/SPECT facilities, and radiopharmacies, enabling efficient production and distribution of short-lived isotopes like ^18F, ^68Ga, and ^99mTc.
Regulatory support from the FDA, including accelerated approval pathways for theranostic agents such as ^177Lu-PSMA-617 (Pluvicto) and ^177Lu-DOTATATE (Lutathera), has fast-tracked commercialization. Leading companies like Novartis, Bayer and Eli Lilly have significant operational bases in the region, ensuring robust supply chains. High per-capita healthcare spending and broad insurance reimbursement encourage adoption of costly but effective radiopharmaceutical therapies, particularly in oncology.
Additionally, a large and growing patient pool for prostate cancer, neuroendocrine tumors, and cardiovascular conditions sustains demand. The presence of top-tier academic and research institutions such as the Mayo Clinic supports continuous clinical trial activity, further driving innovation. Combined with a mature regulatory framework, strong investment climate, and widespread clinical expertise, these factors solidify North America’s leadership in global radiopharmaceuticals market share.
Competitive Landscape
Top companies in the radiopharmaceuticals market include Novartis Pharmaceuticals Corporation, Bayer Corporation, Jubilant DraxImage Inc., Eckert & Ziegler, Telix Pharmaceuticals Limited, and Eli Lilly and Company, among others.
The global radiopharmaceuticals market report delivers a detailed analysis with 58 key tables, more than 70 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Radioisotope
2.5. Snippet by Indication
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Adoption in Various Types of Cancers
3.1.1.2. Regulatory Streamlining for Radioligands
3.1.2. Restraints
3.1.2.1. Nuclear Waste Handling Constraints
3.1.2.2. Stringent Transport & Import/Export Rules
3.1.2.3. Theranostic Expansion to Non-Oncology
3.1.2.4. Radiopharmaceutical–Immunotherapy Combos
Opportunity
3.1.3. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. RADIOPHARMACEUTICALS MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Diagnostic Radiopharmaceuticals*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Therapeutic Radiopharmaceuticals
6. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
6.1.2. Market Attractiveness Index, By Radioisotope
6.2. Technetium-99m*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Fluorine-18
6.4. Gallium-68
6.5. Gallium-67
6.6. Iodine-131
6.7. Lutetium-177
6.8. Yttrium-90
6.9. Others
7. RADIOPHARMACEUTICALS MARKET, BY INDICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.1.2. Market Attractiveness Index, By Indication
7.2. Prostate Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Neuroendocrine Tumors
7.4. Thyroid Cancer
7.5. Bone Tumors
7.6. Hyperthyroidism
7.7. Myocardial Perfusion
7.8. Pulmonary Perfusion
7.9. Vascular Perfusion
7.10. Others
8. RADIOPHARMACEUTICALS MARKET, BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Imaging Centers
8.4. Ambulatory Surgical Centers
8.5. Academic & Research Institutes
8.6. Others
9. RADIOPHARMACEUTICALS MARKET,BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Novartis Pharmaceuticals Corporation*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.4.4. SWOT Analysis
11.2. Bayer Corporation
11.3. Jubilant DraxImage Inc.
11.4. Eckert & Ziegler
11.5. Telix Pharmaceuticals Limited
11.6. Eli Lilly and Company (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Type
2.4. Snippet by Radioisotope
2.5. Snippet by Indication
2.6. Snippet by End-User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Adoption in Various Types of Cancers
3.1.1.2. Regulatory Streamlining for Radioligands
3.1.2. Restraints
3.1.2.1. Nuclear Waste Handling Constraints
3.1.2.2. Stringent Transport & Import/Export Rules
3.1.2.3. Theranostic Expansion to Non-Oncology
3.1.2.4. Radiopharmaceutical–Immunotherapy Combos
Opportunity
3.1.3. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. RADIOPHARMACEUTICALS MARKET, BY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
5.1.2. Market Attractiveness Index, By Type
5.2. Diagnostic Radiopharmaceuticals*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Therapeutic Radiopharmaceuticals
6. RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
6.1.2. Market Attractiveness Index, By Radioisotope
6.2. Technetium-99m*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Fluorine-18
6.4. Gallium-68
6.5. Gallium-67
6.6. Iodine-131
6.7. Lutetium-177
6.8. Yttrium-90
6.9. Others
7. RADIOPHARMACEUTICALS MARKET, BY INDICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.1.2. Market Attractiveness Index, By Indication
7.2. Prostate Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Neuroendocrine Tumors
7.4. Thyroid Cancer
7.5. Bone Tumors
7.6. Hyperthyroidism
7.7. Myocardial Perfusion
7.8. Pulmonary Perfusion
7.9. Vascular Perfusion
7.10. Others
8. RADIOPHARMACEUTICALS MARKET, BY END-USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Imaging Centers
8.4. Ambulatory Surgical Centers
8.5. Academic & Research Institutes
8.6. Others
9. RADIOPHARMACEUTICALS MARKET,BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotope
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Novartis Pharmaceuticals Corporation*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.4.4. SWOT Analysis
11.2. Bayer Corporation
11.3. Jubilant DraxImage Inc.
11.4. Eckert & Ziegler
11.5. Telix Pharmaceuticals Limited
11.6. Eli Lilly and Company (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Radiopharmaceuticals Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Radiopharmaceuticals Market Value, By Radioisotope, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Radiopharmaceuticals Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Radiopharmaceuticals Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Radiopharmaceuticals Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Radiopharmaceuticals Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 8 Global Radiopharmaceuticals Market Value, By Radioisotope, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 10 Global Radiopharmaceuticals Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 12 Global Radiopharmaceuticals Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Radiopharmaceuticals Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Radiopharmaceuticals Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 North America Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 18 North America Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 North America Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Europe Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 23 Europe Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 24 Europe Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Europe Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 South America Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 33 South America Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 34 South America Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Novartis Pharmaceuticals Corporation: Overview
Table 42 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 43 Novartis Pharmaceuticals Corporation: Key Developments
Table 44 Bayer Corporation: Overview
Table 45 Bayer Corporation: Product Portfolio
Table 46 Bayer Corporation: Key Developments
Table 47 Jubilant DraxImage Inc.: Overview
Table 48 Jubilant DraxImage Inc.: Product Portfolio
Table 49 Jubilant DraxImage Inc.: Key Developments
Table 50 Eckert & Ziegler: Overview
Table 51 Eckert & Ziegler: Product Portfolio
Table 52 Eckert & Ziegler: Key Developments
Table 53 Telix Pharmaceuticals Limited: Overview
Table 54 Telix Pharmaceuticals Limited: Product Portfolio
Table 55 Telix Pharmaceuticals Limited: Key Developments
Table 56 Eli Lilly and Company: Overview
Table 57 Eli Lilly and Company: Product Portfolio
Table 58 Eli Lilly and Company: Key Developments
Table 1 Global Radiopharmaceuticals Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Radiopharmaceuticals Market Value, By Radioisotope, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Radiopharmaceuticals Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Radiopharmaceuticals Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Radiopharmaceuticals Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Radiopharmaceuticals Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 8 Global Radiopharmaceuticals Market Value, By Radioisotope, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 10 Global Radiopharmaceuticals Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 12 Global Radiopharmaceuticals Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 14 Global Radiopharmaceuticals Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Radiopharmaceuticals Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 17 North America Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 18 North America Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 North America Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 North America Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 22 Europe Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 23 Europe Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 24 Europe Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 25 Europe Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 32 South America Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 33 South America Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 34 South America Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 35 South America Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Radiopharmaceuticals Market Value, By Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Radiopharmaceuticals Market Value, By Radioisotope, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Radiopharmaceuticals Market Value, By Indication, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Radiopharmaceuticals Market Value, By End-User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Radiopharmaceuticals Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Novartis Pharmaceuticals Corporation: Overview
Table 42 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 43 Novartis Pharmaceuticals Corporation: Key Developments
Table 44 Bayer Corporation: Overview
Table 45 Bayer Corporation: Product Portfolio
Table 46 Bayer Corporation: Key Developments
Table 47 Jubilant DraxImage Inc.: Overview
Table 48 Jubilant DraxImage Inc.: Product Portfolio
Table 49 Jubilant DraxImage Inc.: Key Developments
Table 50 Eckert & Ziegler: Overview
Table 51 Eckert & Ziegler: Product Portfolio
Table 52 Eckert & Ziegler: Key Developments
Table 53 Telix Pharmaceuticals Limited: Overview
Table 54 Telix Pharmaceuticals Limited: Product Portfolio
Table 55 Telix Pharmaceuticals Limited: Key Developments
Table 56 Eli Lilly and Company: Overview
Table 57 Eli Lilly and Company: Product Portfolio
Table 58 Eli Lilly and Company: Key Developments
LIST OF FIGURES
Figure 1 Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 4 Global Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 5 Global Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Radiopharmaceuticals Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Radiopharmaceuticals Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Diagnostic Radiopharmaceuticals Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 9 Therapeutic Radiopharmaceuticals Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Radiopharmaceuticals Market Y-o-Y Growth, By Radioisotope, 2023-2033 (%)
Figure 11 Technetium-99m Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 12 Fluorine-18 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 13 Gallium-68 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 14 Gallium-67 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 15 Iodine-131 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 16 Lutetium-177 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 17 Yttrium-90 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Radiopharmaceuticals Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 20 Prostate Cancer Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 21 Neuroendocrine Tumors Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 22 Thyroid Cancer Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 23 Bone Tumors Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 24 Hyperthyroidism Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 25 Myocardial Perfusion Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 26 Pulmonary Perfusion Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 27 Vascular Perfusion Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 28 Others Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Radiopharmaceuticals Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 30 Hospitals End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 31 Diagnostic Imaging Centers End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 32 Ambulatory Surgical Centers End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 33 Academic & Research Institutes End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 34 Others End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 35 Global Radiopharmaceuticals Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 36 North America Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 37 North America Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 38 North America Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 39 North America Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 40 North America Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 41 North America Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 42 Europe Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 43 Europe Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 44 Europe Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 45 Europe Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 46 Europe Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 47 Europe Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 48 Asia-Pacific Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 49 Asia-Pacific Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 50 Asia-Pacific Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 51 Asia-Pacific Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 52 Asia-Pacific Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 53 Asia-Pacific Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 54 South America Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 55 South America Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 56 South America Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 57 South America Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 58 South America Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 59 South America Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 60 Middle East and Africa Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 61 Middle East and Africa Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 62 Middle East and Africa Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 63 Middle East and Africa Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 64 Middle East and Africa Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 65 Novartis Pharmaceuticals Corporation: Financials
Figure 66 Bayer Corporation: Financials
Figure 67 Jubilant DraxImage Inc.: Financials
Figure 68 Eckert & Ziegler: Financials
Figure 69 Telix Pharmaceuticals Limited: Financials
Figure 70 Eli Lilly and Company: Financials
Figure 1 Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 3 Global Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 4 Global Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 5 Global Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 6 Global Radiopharmaceuticals Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Radiopharmaceuticals Market Y-o-Y Growth, By Type, 2023-2033 (%)
Figure 8 Diagnostic Radiopharmaceuticals Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 9 Therapeutic Radiopharmaceuticals Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Radiopharmaceuticals Market Y-o-Y Growth, By Radioisotope, 2023-2033 (%)
Figure 11 Technetium-99m Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 12 Fluorine-18 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 13 Gallium-68 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 14 Gallium-67 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 15 Iodine-131 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 16 Lutetium-177 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 17 Yttrium-90 Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Radioisotope in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Radiopharmaceuticals Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 20 Prostate Cancer Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 21 Neuroendocrine Tumors Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 22 Thyroid Cancer Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 23 Bone Tumors Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 24 Hyperthyroidism Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 25 Myocardial Perfusion Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 26 Pulmonary Perfusion Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 27 Vascular Perfusion Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 28 Others Indication in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Radiopharmaceuticals Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 30 Hospitals End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 31 Diagnostic Imaging Centers End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 32 Ambulatory Surgical Centers End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 33 Academic & Research Institutes End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 34 Others End-User in Global Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 35 Global Radiopharmaceuticals Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 36 North America Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 37 North America Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 38 North America Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 39 North America Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 40 North America Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 41 North America Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 42 Europe Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 43 Europe Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 44 Europe Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 45 Europe Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 46 Europe Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 47 Europe Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 48 Asia-Pacific Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 49 Asia-Pacific Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 50 Asia-Pacific Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 51 Asia-Pacific Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 52 Asia-Pacific Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 53 Asia-Pacific Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 54 South America Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 55 South America Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 56 South America Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 57 South America Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 58 South America Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 59 South America Radiopharmaceuticals Market Share, By Country, 2024 & 2033 (%)
Figure 60 Middle East and Africa Radiopharmaceuticals Market Value, 2022-2033 (US$ Billion)
Figure 61 Middle East and Africa Radiopharmaceuticals Market Share, By Type, 2024 & 2033 (%)
Figure 62 Middle East and Africa Radiopharmaceuticals Market Share, By Radioisotope, 2024 & 2033 (%)
Figure 63 Middle East and Africa Radiopharmaceuticals Market Share, By Indication, 2024 & 2033 (%)
Figure 64 Middle East and Africa Radiopharmaceuticals Market Share, By End-User, 2024 & 2033 (%)
Figure 65 Novartis Pharmaceuticals Corporation: Financials
Figure 66 Bayer Corporation: Financials
Figure 67 Jubilant DraxImage Inc.: Financials
Figure 68 Eckert & Ziegler: Financials
Figure 69 Telix Pharmaceuticals Limited: Financials
Figure 70 Eli Lilly and Company: Financials
